Development, characterization and distribution of adoptively transferred peripheral blood lymphocytes primed by human papillomavirus 18 E7 - Pulsed autologous dendritic cells in a patient with metastatic adenocarcinoma of the uterine cervix

We describe a 27-year-old woman with systemic chemoresistant and radioresistant metastatic disease secondary to a recurrence of human papillomavirus (HPV) 18 infected cervical adenocarcinoma of the uterine cervix who received adoptive transfer of peripheral blood T cells stimulated with HPV 18 E7-pulsed autologous dendritic cells (DC). Extensive in vitro characterization of the DC-activated T cells derived from peripheral blood mononuclear cells (PBMC) included phenotypic analysis, cytotoxicity and intracellular cytokine production. High cytotoxicity activity was observed by CD8+T cells against autologous tumor cells, but not against NK-sensitive K562 cells, autologous Con-A lymphoblasts, or autologous Epstein-Barr virus-transformed lymphoblastoid cells. Blocking studies demonstrated that lytic activity was significantly inhibited by pretreatment of tumor targets with MAb specific for HLA class I as well as that of effector cells with anti-CD8, anti-LFA-1, but not anti CD3 MAb. Two-color flow cytometric analysis of the cytotoxic T cells revealed that a significant proportion of CD8+ cells was also CD56+. These double positive CTLs were thymically derived, as shown by expression of heterodimeric CD8 molecules (alpha/beta CD8) and were endowed with high cytotoxic activity against tumor cells. Analysis of intracellular cytokine expression showed that the striking majority of E7-pulsed DC activated CD8+ T cells strongly expressed IFN-gamma, TNF-alpha and IL-2 but not IL-4. The patient received two infusions of cytotoxic tumor-specific T cells at 2 week intervals, and in vivo distribution of the T cells was followed by 111 oxine labeling and serial gamma camera imaging. Persistent accumulation of radioactivity in the lungs, which harbored extensive metastatic disease, was detected up to 120 hrs after the infusion. Taken together, these results illustrate the potential of E7-specific and tumor-specific CTL-based immunotherapy for the treatment of patients with invasive cervical cancer.

Cervical cancer; HPV; CTLs; Dentritic cells; Adoptive immunotherapy

[1] Bosch F. X.,M anosM .M .,M unoz N. et al.: " Prevalence of human papillomavirus in cervical cancer: a worldwide perspective". J. Natl. Cancer Inst., 1995, 87, 796.

[2] Brinton L.A.: "Epidemiology of cervical cancer: overview". In: N.M unoz, F. Bosch, K. V. Shah,A .M eheus (eds.): The epidemiology of human papillomavirus and cervical cancer. Lyon, France; IARC Science Publications, 1992, 119, 3.

[3] Steinman R. M.:'The dendritic cell system and its role in immunogenicity". Ann. Rev. lmmunol., 1991, 9,271.

[4] Young J. W.,I naba K.: " Dendritic cells as adjuvants for Class I major histocompatibility complex-restricted antitumor immunity". J. Exp. Med., 1996, 183, 7.

[5] Romani N., Gruner S.,B rang D. et al.: " Proliferating dendritic cell progenitors in human blood". J. Exp. Med., 1994, 180, 83.

[6] Santin A. D., Hermonat P. L., Ravaggi A. et al.: "Induction of human papillomavirus-specific CD4+ and CDS+ lymphocytes by E7 pulsed autologous dendritic cells in patients with HPV 16 and 18 positive cervical cancer". J. Virol., 1999, 73, 5402.

[7] Mclntrye M. C., Ruesch M. N., Laimins L. A.:''Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and pl07". Virology, 1996, 215, 73.

[8] Hopkins K. A.: "Basic microlymphocytotoxicity test". In "ASHI manual". Lenexa (KS),A merican Society for Histocompatibility and Immunogenetics, 1990, 195.

[9] Openshaw P. J.M.,M urphy E. E., Hosken N. A. et al.: " Heterogeneity of intracellular cytokine synthesis at the single cell level in polarized T helpcr I and T helper 2 populations". J. Exp. Med., 1995, 182, 1357.

[10] Lu P.-H., Negrin R. S.: "A novel population of expanded human CD3+ CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency". J. Immunol., 1994, 153, 1687.

[11] Takii Y., Hashimoto S.,I iai T.,W atanabe H.,H atakeyama K.,A boT .: "Increase in the proportion of granulated CD56+ T cells in patients with malignancy". Clin. Exp. Immunol., 1994, 97, 522.

[12] Satoh M., Seki S., Hashimoto W. et al.: " Cytotoxic γ/δ) or α/β T cells with a natural k仆!er cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2". J. lmmunol., 1996, 157, 3886.

[13] von Boehmer H.,K irberg J.,R ocha B.: "An unusual lineage of α/β T cells that contains autoreactive cells". J. Exp. Med., 1991, 174, 1001.

[14] Rocha B., Vassalli P., Guy-Grand D.: "The extrathymic T cell development pathway". lmmunol. Today, 1992, 13, 449.

[15] Doherty P. C.,T ripp R. E., Sixb ey J. W.: "Evasion of host immune responses by tumors and viruses". In: "Vaccines Against Virally Induced Cancers". Wiley, Chichester (Ciba Foundation Symposium, 187), 1994, 245.

[16] Durst M., Glitz D., Schneider A., zur Hausen A.: " Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridisation". Virology, 1992, 189, 132.

[17] Yukawa K., Butz K., Yasui T., Kikutani H., Hoppe-Seyler F.: " Regulation of human papillomavirus transcription by the differentiation-dependent epithelial factor Epoc-1 sknla". J. Virol., 1996, 70, 10.

[18] Chambers M.A., Wei Z., Coleman N., Nash A. A., Stanley M. A: " 'Natural' presentation of human papillomavirus type-16 E7 protein to immunocompetent mice results in antigen-specific sensitization or sustained unresponiveness". Eur. J. Immunol., 1994, 24, 738.

[19] Melero I.,S ingha] M. C.,M cGowan P. et al.: "Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus 16". J. Virol., 1997, 71, 3998.

[20] Moretta A., P antaleo G., Mingari M. C., Melioli G., Moretta L., Cerottini J.-C.: "Assignment of human natural killer (NK) like cells to the T-cell lineage. Single allospecific Tcell clones lyse specific or NK-sensitive target cells via distinct recognition structures". Eur. J. Jmmunol., 1984, 14, 121.

[21] Thiele D. L., Lipsky P. E.: "The role of cell surface recognition structures in the initiation of MHC-unrestricted 'promiscuous' killing by T cells". Immunol. Today, 1989, 10, 375.

[22] Hilders C. G. J. M., Ras L., Van Eendenburg J. D. H., Nooyen Y., Fleuren G. J.: "Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma". Int. J. Cancer, 1994, 57, 805.

[23] Read E. J., Keenan A. M., Carter C. S., Yolles P. S., Davey R. J.: "In vivo traffic of Indium'"oxine labelled human lymphocytes collected by automated apheresis". J. Nucl. Med., 1986, 31,999.

[24] P ockaj B. A., Sherry R. M., Wei J.P. et al.: "Localization of"'Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy". Cancer, 1994, 73, 1731.

[25] Hsu F. J., Benike C., Fagnoni F. et al.: "Vaccination of patients with B-cell lymphoma using autologous antigenpulsed dendritic cells". Nature Med., 1996, 2, 52.

[26] Nestle F. 0., Alijagic S., Gilliet M. et al.: "Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells". Nature Med., 1998, 4, 328.